Literature DB >> 10789937

Percutaneous closure of patent ductus arteriosus: complementary use of detachable Cook patent ductus arteriosus coils and Amplatzer duct occluders.

T Podnar1, P Gavora, J Masura.   

Abstract

UNLABELLED: Several different devices were evaluated for the percutaneous closure of patent ductus arteriosus (PDA), and important drawbacks were found in all of them. To overcome these drawbacks, both detachable Cook PDA coils and Amplatzer duct occluders (ADO) were used for the percutaneous closure of PDA. A total of 54 patients underwent transcatheter occlusion of PDA at a median age of 4.5 years (range 0.5-29 years) and at a median weight of 19.5 kg (range 6-69 kg). Three patients were adults. Detachable Cook PDA coils were used in 26 patients with a median PDA diameter of 1.7 mm (range 1.1-2.2 mm) and ADO were used in 28 patients with a median PDA diameter of 3.8 mm (range 1.9-7.5 mm). Devices were successfully implanted in all 54 patients. Complete closure was achieved in 53 of 54 patients (98% closure rate). Median fluoroscopy time was 12 min (range 4-47 min).
CONCLUSION: According to our experience, the complementary use of detachable Cook patent ductus arteriosus coils and Amplatzer duct occluders for the percutaneous closure of PDA can be recommended.

Entities:  

Mesh:

Year:  2000        PMID: 10789937     DOI: 10.1007/s004310050073

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  2 in total

1.  Preclosure pressure gradients predict patent ductus arteriosus patients at risk for later left pulmonary artery stenosis.

Authors:  Srinath T Gowda; Shelby Kutty; Makram Ebeid; Athar M Qureshi; Sarah Worley; Larry A Latson
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

2.  Percutaneous transaortic occlusion of patent ductus arteriosus using a new versatile angiographic and delivery catheter.

Authors:  A Lorber; A Z Gazit; A Khoury; Y Schwartz; F Freudental
Journal:  Pediatr Cardiol       Date:  2003 Sep-Oct       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.